Lunai Bioworks (LNAI) Operating Margin (2013 - 2026)
Lunai Bioworks (LNAI) posted quarterly Operating Margin of 7054.05% for Q1 2026, up 97.43% quarter-over-quarter from 274996.31% in Q2 2016.
Lunai Bioworks (LNAI) Operating Margin (2013 - 2026) Analysis & Trends
Lunai Bioworks' Operating Margin history runs 3 years deep, the most recent figure standing at 7054.05% for Q1 2026.
- In Q1 2026, Operating Margin changed N/A year-over-year to 7054.05%; the TTM figure through Mar 2026 stood at 156672.97% (changed N/A YoY), while the FY2016 annual figure was 4959.04%, changed N/A from the prior year.
- Operating Margin for Q1 2026 stood at 7054.05%, up from 274996.31% in the prior quarter.
- The five-year high for Operating Margin was 7054.05% in Q1 2026, with the low at 7054.05% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 19.75% |
| 10 | Lunai Bioworks | 7.03 Mn | 3.87 Mn | 20,942.00 | -7,054.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,054.05% |
| Jun 30, 2016 | -274,996.31% |
| Sep 30, 2013 | -2,347.50% |
| Jun 30, 2013 | -1,341.26% |
| Mar 31, 2013 | -571.85% |